Acurian Patients

In-practice Patients

68%

32%

Contribution of US Patient Randomizations

ACURIAN CASE STUDY:

Predictable, reliable, and measureable results

Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.

(continued on other side)

Acurian Delivers 32% of US Patient Randomizations to an Asthma Program

Sites faced significant enrollment challenges caused by a difficult protocol. To qualify, patients must have had two or more exacerbations in the past year; a high dose of inhaled corticosteroids was required; the study duration was long; and the drug was an injectable form. As a result, enrollment faltered, and a significant delay was projected – a major delay that was unacceptable in such a tight race to market.

The clinical trial team needed a reliable solution to close the gap, so they hired Acurian to support two protocols across US sites. Acurian delivered 32% (120) of all US randomizations, over the time of its engagement.

Acurian was the most effective enrollment solution, as well as the most cost-effective solution.Acurian cost $12.1 million less than waiting seven months or more for sites to find enough patients and $7.7 million less than adding 129 sites (for a total of 399), which would have been required to reach the same enrollment volume in the same period of time.*

*IMS CRO CostPro® analysis

WHEN YOU CAN’T AFFORD A DELAY IN PATIENT ENROLLMENT

Acurian, Inc. is the leading full-service provider of global patient enrollment and retention solutions for the life sciences industry. For the past 20 years, our unique patient-first approach has provided sponsors with enrollment certainty by delivering the patients they need, when and where they need them.

The Global Enrollment & Retention Specialist

www.acurian.com enrollment.certainty@acurian.com212520178

United StatesHorsham, Pennsylvania 215.323.9000

EuropeCambridge, United Kingdom +44 1223 374799

Acurian accelerated enrollment by over seven months for both protocols.By increasing sites’ enrollment rates, Acurian shortened the enrollment timelines for protocols 1 and 2 by 6 months and 7.7 months, respectively.

_______________________________________________________________

_______________________________________________________________

_______________________________________________________________

_______________________________________________________________

_______________________________________________________________

$25.0

$20.0

$15.0

$10.0

$5.0

$0.0Acurian Wait for 270 SItes

to CompleteEnrollment

$7.8$12.2

$19.9

Add 129 SItes(399 total)

$ M

illio

ns

Cost to Enroll 120 Patients

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

_________________________________________________________________________________________________

400

350

300

250

200

150

100

50

0

Months

With Acurian - 7.1 Month Time Savings

I I I I I I I I I I I I I I I I I I I I I I I

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

In-Practice Randomizations ActualsTotal Randomizations With Acurian In-Practice (Forecasted) Randomizations

Randomization Volume over Time Protocols 1 and 2